197 related articles for article (PubMed ID: 20363737)
1. Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G.
Cen S; Peng ZG; Li XY; Li ZR; Ma J; Wang YM; Fan B; You XF; Wang YP; Liu F; Shao RG; Zhao LX; Yu L; Jiang JD
J Biol Chem; 2010 May; 285(22):16546-52. PubMed ID: 20363737
[TBL] [Abstract][Full Text] [Related]
2. Identification of small molecule compounds targeting the interaction of HIV-1 Vif and human APOBEC3G by virtual screening and biological evaluation.
Ma L; Zhang Z; Liu Z; Pan Q; Wang J; Li X; Guo F; Liang C; Hu L; Zhou J; Cen S
Sci Rep; 2018 May; 8(1):8067. PubMed ID: 29795228
[TBL] [Abstract][Full Text] [Related]
3. Function analysis of sequences in human APOBEC3G involved in Vif-mediated degradation.
Zhang L; Saadatmand J; Li X; Guo F; Niu M; Jiang J; Kleiman L; Cen S
Virology; 2008 Jan; 370(1):113-21. PubMed ID: 17916373
[TBL] [Abstract][Full Text] [Related]
4. The dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3G.
Miller JH; Presnyak V; Smith HC
Retrovirology; 2007 Nov; 4():81. PubMed ID: 18036235
[TBL] [Abstract][Full Text] [Related]
5. Functional analysis of the two cytidine deaminase domains in APOBEC3G.
Li X; Ma J; Zhang Q; Zhou J; Yin X; Zhai C; You X; Yu L; Guo F; Zhao L; Li Z; Zeng Y; Cen S
Virology; 2011 Jun; 414(2):130-6. PubMed ID: 21489586
[TBL] [Abstract][Full Text] [Related]
6. Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors.
Henriet S; Mercenne G; Bernacchi S; Paillart JC; Marquet R
Microbiol Mol Biol Rev; 2009 Jun; 73(2):211-32. PubMed ID: 19487726
[TBL] [Abstract][Full Text] [Related]
7. APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete "all or nothing" phenomenon.
Armitage AE; Deforche K; Chang CH; Wee E; Kramer B; Welch JJ; Gerstoft J; Fugger L; McMichael A; Rambaut A; Iversen AK
PLoS Genet; 2012; 8(3):e1002550. PubMed ID: 22457633
[TBL] [Abstract][Full Text] [Related]
8. The level of APOBEC3G (hA3G)-related G-to-A mutations does not correlate with viral load in HIV type 1-infected individuals.
Ulenga NK; Sarr AD; Hamel D; Sankale JL; Mboup S; Kanki PJ
AIDS Res Hum Retroviruses; 2008 Oct; 24(10):1285-90. PubMed ID: 18851679
[TBL] [Abstract][Full Text] [Related]
9. Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC.
Zuo T; Liu D; Lv W; Wang X; Wang J; Lv M; Huang W; Wu J; Zhang H; Jin H; Zhang L; Kong W; Yu X
J Virol; 2012 May; 86(10):5497-507. PubMed ID: 22379088
[TBL] [Abstract][Full Text] [Related]
10. Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.
Pery E; Sheehy A; Nebane NM; Brazier AJ; Misra V; Rajendran KS; Buhrlage SJ; Mankowski MK; Rasmussen L; White EL; Ptak RG; Gabuzda D
J Biol Chem; 2015 Apr; 290(16):10504-17. PubMed ID: 25724652
[TBL] [Abstract][Full Text] [Related]
11. Induction of heat-shock protein 70 by prostaglandin A₁ inhibits HIV-1 Vif-mediated degradation of APOBEC3G.
Sugiyama R; Abe M; Nishitsuji H; Murakami Y; Takeuchi H; Takaku H
Antiviral Res; 2013 Sep; 99(3):307-11. PubMed ID: 23831493
[TBL] [Abstract][Full Text] [Related]
12. Host apolipoprotein B messenger RNA-editing enzyme catalytic polypeptide-like 3G is an innate defensive factor and drug target against hepatitis C virus.
Peng ZG; Zhao ZY; Li YP; Wang YP; Hao LH; Fan B; Li YH; Wang YM; Shan YQ; Han YX; Zhu YP; Li JR; You XF; Li ZR; Jiang JD
Hepatology; 2011 Apr; 53(4):1080-9. PubMed ID: 21480314
[TBL] [Abstract][Full Text] [Related]
13. Nuclear Exclusion of the HIV-1 host defense factor APOBEC3G requires a novel cytoplasmic retention signal and is not dependent on RNA binding.
Bennett RP; Presnyak V; Wedekind JE; Smith HC
J Biol Chem; 2008 Mar; 283(12):7320-7. PubMed ID: 18165230
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of tRNA₃(Lys)-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication.
Guo F; Cen S; Niu M; Saadatmand J; Kleiman L
J Virol; 2006 Dec; 80(23):11710-22. PubMed ID: 16971427
[TBL] [Abstract][Full Text] [Related]
15. A novel HIV-1 inhibitor that blocks viral replication and rescues APOBEC3s by interrupting vif/CBFβ interaction.
Duan S; Wang S; Song Y; Gao N; Meng L; Gai Y; Zhang Y; Wang S; Wang C; Yu B; Wu J; Yu X
J Biol Chem; 2020 Oct; 295(43):14592-14605. PubMed ID: 32817167
[TBL] [Abstract][Full Text] [Related]
16. Identification of an HIV-1 replication inhibitor which rescues host restriction factor APOBEC3G in Vif-APOBEC3G complex.
Zhang S; Zhong L; Chen B; Pan T; Zhang X; Liang L; Li Q; Zhang Z; Chen H; Zhou J; Luo H; Zhang H; Bai C
Antiviral Res; 2015 Oct; 122():20-7. PubMed ID: 26241003
[TBL] [Abstract][Full Text] [Related]
17. APOBEC3G-UBA2 fusion as a potential strategy for stable expression of APOBEC3G and inhibition of HIV-1 replication.
Li L; Liang D; Li JY; Zhao RY
Retrovirology; 2008 Aug; 5():72. PubMed ID: 18680593
[TBL] [Abstract][Full Text] [Related]
18. Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G.
Schröfelbauer B; Senger T; Manning G; Landau NR
J Virol; 2006 Jun; 80(12):5984-91. PubMed ID: 16731937
[TBL] [Abstract][Full Text] [Related]
19. [Advances in the study of molecular mechanism of APOBEC3G anti-HIV-1].
Fan B; Cen S; Jiang JD
Yao Xue Xue Bao; 2008 Jul; 43(7):678-82. PubMed ID: 18819469
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 Vif binds to APOBEC3G mRNA and inhibits its translation.
Mercenne G; Bernacchi S; Richer D; Bec G; Henriet S; Paillart JC; Marquet R
Nucleic Acids Res; 2010 Jan; 38(2):633-46. PubMed ID: 19910370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]